62 related articles for article (PubMed ID: 21195878)
41. Alpha emitting nuclides for targeted therapy.
Hatcher-Lamarre JL; Sanders VA; Rahman M; Cutler CS; Francesconi LC
Nucl Med Biol; 2021 Jan; 92():228-240. PubMed ID: 33558017
[TBL] [Abstract][Full Text] [Related]
42. Targeting DNA Damage Response in Prostate and Breast Cancer.
Wengner AM; Scholz A; Haendler B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158305
[TBL] [Abstract][Full Text] [Related]
43. The Effect of
Gao Y; Tang X; Cao J; Rong R; Yu Z; Liu Y; Lu Y; Liu X; Han L; Liu J; Zhang J; Xu M; Liu F
J Cancer; 2019; 10(2):378-387. PubMed ID: 30719131
[No Abstract] [Full Text] [Related]
44. α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2.
Poty S; Francesconi LC; McDevitt MR; Morris MJ; Lewis JS
J Nucl Med; 2018 Jul; 59(7):1020-1027. PubMed ID: 29496984
[TBL] [Abstract][Full Text] [Related]
45. Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors.
Honarvar H; Westerlund K; Altai M; Sandström M; Orlova A; Tolmachev V; Karlström AE
Theranostics; 2016; 6(1):93-103. PubMed ID: 26722376
[TBL] [Abstract][Full Text] [Related]
46. Experimental therapeutics in prostate cancer: where are we now and where do we need to go.
Sartor O
Asian J Androl; 2012 May; 14(3):421-2. PubMed ID: 22522500
[No Abstract] [Full Text] [Related]
47. Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.
Abbas N; Heyerdahl H; Bruland OS; Borrebæk J; Nesland J; Dahle J
EJNMMI Res; 2011 Aug; 1(1):18. PubMed ID: 22214432
[TBL] [Abstract][Full Text] [Related]
48. An overview of targeted alpha therapy.
Kim YS; Brechbiel MW
Tumour Biol; 2012 Jun; 33(3):573-90. PubMed ID: 22143940
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
50. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.
Heyerdahl H; Krogh C; Borrebæk J; Larsen Å; Dahle J
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):563-70. PubMed ID: 21195878
[TBL] [Abstract][Full Text] [Related]
51. In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.
Dahle J; Krogh C; Melhus KB; Borrebaek J; Larsen RH; Kvinnsland Y
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):886-95. PubMed ID: 19679402
[TBL] [Abstract][Full Text] [Related]
52. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
Abbas N; Bruland ØS; Brevik EM; Dahle J
Nucl Med Commun; 2012 Aug; 33(8):838-47. PubMed ID: 22643311
[TBL] [Abstract][Full Text] [Related]
53. Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate.
Zhang DY; Li Y; Rizvi SM; Qu C; Kearsley J; Allen BJ
Cancer Lett; 2005 Feb; 218(2):181-90. PubMed ID: 15670895
[TBL] [Abstract][Full Text] [Related]
54. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.
Heyerdahl H; Abbas N; Brevik EM; Mollatt C; Dahle J
PLoS One; 2012; 7(8):e42345. PubMed ID: 22879947
[TBL] [Abstract][Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
